SGMT +120% on phase-2b NASH data: https://www.globenewswire.com/news-release/2024/01/22/2812908/0/en/Sagimet-Biosciences-Announces-Positive-Topline-Results-from-Phase-2b-FASCINATE-2-Clinical-Trial-of-Denifanstat-in-Biopsy-Confirmed-F2-F3-NASH.html Even after today’s bounce, the share price is slightly below the $16 IPO price from Jul 2023 (#msg-172342214).